On December 1, 2023, Michael Kalb announced resignation from his position as Chief Financial Officer of Impel Pharmaceuticals Inc. with his last day to be December 31, 2023.
IPI Legacy Liquidation Co
Equities
IMPL
US45258K1097
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.015 USD | 0.00% | 0.00% | -87.85% |
Apr. 12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
Apr. 05 | North American Morning Briefing : Investors on -2- | DJ |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- IMPL Stock
- News IPI Legacy Liquidation Co
- Impel Pharmaceuticals Inc. Announces Resignation of Michael Kalb as Chief Financial Officer, Effective on December 31, 2023